1. Scrip
  2. >>Business
  3. >>Strategy

Say Goodbye To NASH And Hello To MASH

 
• By Joseph Haas

The revised nomenclature of metabolic dysfunction-associated steatohepatitis (MASH), rather than non-alcoholic steatohepatitis (NASH), appears to be taking hold among stakeholders in the liver disease space.

Name change
The biopharma industry gradually is adapting to the name change from NASH to MASH • Source: Shutterstock

The shift in terminology from NASH to MASH seems to be taking hold judging by public statements from companies working in the space, as well as some of the market analysts commenting on developments in metabolic dysfunction-associated steatohepatitis, the disease formerly known as non-alcoholic steatohepatitis.

The nomenclature change is intended to de-stigmatize the disease by eliminating references to alcohol use and fatty liver and also clarify what degree of alcohol consumption falls outside the definition of the disease, so that a possibly

Key Takeaways

  • Stakeholders groups are encouraging the use of a new acronym – MASH – to replace the existing NASH in an effort destigmatize the disease.

  • Four months after rollout of the new nomenclature at AASLD, MASH seems to be gaining use, although some sponsors and financial firms are using both terms

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.